Lung Cancer Vaccine to Undergo Testing in the U.S.

Lung Cancer Vaccine pic
Lung Cancer Vaccine

As a doctoral student and part of the Black Lab at the University of Kentucky, Sherif El-Refai assists in research that develops cognitive cancer treatments. Sherif El-Refai, a student of clinical and experimental therapeutics, focuses particularly on cancers of the lung.

In October 2016, the U.S. Food and Drug Administration announced approval of a vaccine for lung cancer originally developed in Havana, Cuba. The vaccine is known as CIMAvax-EGF and will undergo testing in combination with Opdivo, an immunotherapy pharmaceutical that scientists believe may affect the vaccine’s effectiveness.

The vaccine has already received approval in several countries, where results show only a few months of added life expectancy for recipients. However, researchers at the Roswell Park Cancer Institute in Buffalo, New York, hope to find enough benefits to suggest the vaccine as a potential treatment for a disease that is difficult to treat.

The drug works to control cancer growth by targeting the epidermal growth factor protein, which drives cell growth. By stimulating the body to create antibodies that attack this protein, CIMAvax-EGF prevents it from promoting the growth of cancer cells. Although the results thus far are moderate, researchers hope that it may become an early tool for slowing cancer growth or for improving the quality of life for patients with later-stage tumors.

Published by

Sherif El-Refai

Sherif El-Refai is a recent graduate of the University of Florida’s Hough Graduate School of Business. He received a Masters of Business Administration with a concentration in competitive strategy along with the market and global management. He has experience of working as a pharmacy technician.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s